SCHEMBL3762095

SCHEMBL3762095

O=C1CCCN1c1cccc(Nc2nccc(-c3c(Cl)nc4ccccn34)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 8/20 0.54
PRKD3 O94806 3/20 0.53
LCK P06239 3/20 0.53
FGFR1 P11362 3/20 0.53
SRC P12931 3/20 0.53
KDR P35968 3/20 0.53
SYK P43405 3/20 0.53
GSK3A P49840 3/20 0.53
GSK3B P49841 3/20 0.53
TAOK1 Q7L7X3 3/20 0.53
AURKB Q96GD4 3/20 0.53
SLK Q9H2G2 3/20 0.53
MAP3K20 Q9NYL2 3/20 0.53
MAP4K5 Q9Y4K4 3/20 0.53
KIT P10721 2/20 0.53
CSF1R P07333 2/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
ROS1 P08922 1/20 0.53
FLT1 P17948 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789032 0.82 IGF1R (0.67) CDK2PRKD3LCKFGFR1SRC
SCHEMBL3765211 0.81 CAMK2D (0.61) CDK2PRKD3LCKFGFR1SRC
SCHEMBL1786852 0.79 IGF1R (0.80) PRKD3LCKFGFR1SRCKDR
SCHEMBL1785338 0.79 IGF1R (0.58) CDK2PRKD3LCKFGFR1SRC
SCHEMBL1788152 0.79 IGF1R (0.81) PRKD3LCKFGFR1SRCKDR
SCHEMBL3760568 0.79 CDK2 (0.74) CDK2PRKD3LCKFGFR1SRC
SCHEMBL1789944 0.79 BRAF (0.70) PRKD3LCKFGFR1SRCKDR
SCHEMBL1785252 0.79 IGF1R (0.70) PRKD3LCKFGFR1SRCKDR
SCHEMBL1790090 0.78 IGF1R (0.67) CDK2PRKD3LCKFGFR1SRC
SCHEMBL1786114 0.78 IGF1R (0.66) PRKD3LCKFGFR1SRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 CDK2 3/4885PRKD3 280/4885LCK 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.